Sanara MedTech price to book ratio SMTI
Market value divided by the book value of the company's net assets, since 2011.
- Today, Oct 23, 2026
- 37.9×
- 9-year median
- 7.7×
- Against its 9-year history
- 92nd
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 4.5× to 138×
- Peer median
- 2.6×
Sanara MedTech's price to book ratio is 37.9× as of Oct 23, 2026.
That is above its 9-year median of 7.7×, higher than on 92% of days in the last 9 years.
Over that time it ranged from 4.5× in Dec 2018 to 138× in Apr 2018.
The median for 10 medical instruments and supplies stocks of a similar size is 2.6×.
Price to book ratio over time
The dashed line is the 9-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 37.9× | 25.5× | 44.5× |
| 2025 | 35.2× | 5.9× | 37.7× |
| 2024 | 7.4× | 5.4× | 8.3× |
| 2023 | 7.9× | 5.6× | 9.7× |
| 2022 | 8.3× | 4.8× | 8.3× |
| 2021 | 6.7× | 5.7× | 45.8× |
| 2020 | 53.7× | 7.5× | 55.6× |
| 2019 | 8.2× | 5.9× | 10.6× |
| 2018 | 5.9× | 4.5× | 138× |
| 2017 | n/m a value too high to mean anything | ||
| 2016 | n/m a value too high to mean anything | ||
| 2015 | n/m a value too high to mean anything | ||
| 2014 | 19.4× | 17.3× | 25.9× |
| 2013 | n/m a value too high to mean anything | ||
| 2012 | 2.7× | 2.2× | 4.6× |
| 2011 | 4.8× | 2.5× | 4.8× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Sanara MedTech's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| SMTISanara MedTech | 37.9× |
| INFUInfuSystem | 4.7× |
| EMBCEmbecta | n/m |
| UTMDUtah Medical Products | 1.9× |
| PDEXPro DEX | 4.2× |
| TCMDTactile Systems Technology | 2.4× |
| MDXGMimedx | 2.6× |
| MOVMovado | 1.4× |
| KEQUKewaunee Scientific | 1.3× |
| IRMDIradimed | 10.8× |
| STAAStaar Surgical | 3.1× |
| Peer median | 2.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Sanara MedTech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.